About revenio group - REVXF
Revenio Group Oyj engages in ophthalmic diagnostics and the manufacture and sale of ophthalmic devices. The firm's ophthalmic diagnostic solutions include intraocular pressure measurement devices under the iCare brand, retinal imaging devices, and perimeters. It operates through the following geographical segments: Finland, Other Europe, North America, and Others. The company was founded in 2001 and is headquartered in Vantaa, Finland.
REVXF At a Glance
Revenio Group Oyj
Härkähaankuja 7
Vantaa, Uusimaa 01730
| Phone | 358-9-8775-1150 | Revenue | 111.97M | |
| Industry | Medical Specialties | Net Income | 20.01M | |
| Sector | Health Technology | 2024 Sales Growth | 7.244% | |
| Fiscal Year-end | 12 / 2025 | Employees | 241 | |
| View SEC Filings |
REVXF Valuation
| P/E Current | 32.675 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 36.586 |
| Price to Sales Ratio | 6.538 |
| Price to Book Ratio | 6.564 |
| Price to Cash Flow Ratio | 28.35 |
| Enterprise Value to EBITDA | 22.389 |
| Enterprise Value to Sales | 6.465 |
| Total Debt to Enterprise Value | 0.018 |
REVXF Efficiency
| Revenue/Employee | 464,619.842 |
| Income Per Employee | 83,020.888 |
| Receivables Turnover | 6.672 |
| Total Asset Turnover | 0.746 |
REVXF Liquidity
| Current Ratio | 2.176 |
| Quick Ratio | 1.708 |
| Cash Ratio | 0.958 |
REVXF Profitability
| Gross Margin | 43.151 |
| Operating Margin | 23.861 |
| Pretax Margin | 23.785 |
| Net Margin | 17.869 |
| Return on Assets | 13.326 |
| Return on Equity | 18.035 |
| Return on Total Capital | 16.036 |
| Return on Invested Capital | 16.461 |
REVXF Capital Structure
| Total Debt to Total Equity | 11.868 |
| Total Debt to Total Capital | 10.609 |
| Total Debt to Total Assets | 8.988 |
| Long-Term Debt to Equity | 6.795 |
| Long-Term Debt to Total Capital | 6.074 |